Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acomplia To Launch In July In Europe For Obesity Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi-Aventis’ rimonabant is currently “approvable” at FDA for obesity.

You may also be interested in...



Suicide Associated With Sanofi-Aventis’ Acomplia, U.K. Agency Says

One suicide and 48 suicidal ideation cases reported following treatment with Acomplia between June 2006 and May 9.

Suicide Associated With Sanofi-Aventis’ Acomplia, U.K. Agency Says

One suicide and 48 suicidal ideation cases reported following treatment with Acomplia between June 2006 and May 9.

Sanofi-Aventis’ Rimonabant Cuts Visceral Fat

ADAGIO-LIPIDS trial shows HDL cholesterol boost but not LDL.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS064362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel